CellMark and its CEO lacked scientific evidence to back up their products’ claims
CellMark Biopharma, LLC and its CEO have agreed to settle Federal Trade Commission charges that they made false or unsupported claims regarding two health products they marketed as effective treatments for cancer patients’ malnutrition and “chemo fog,” or treatment-related cognitive dysfunction

See the full post at FTC.gov